The Department of Justice (DOJ) recently obtained a civil judgment against an individual from Mississippi, ordering him to pay more than $31 million for his role in orchestrating a nationwide healthcare kickback scheme involving federally funded programs. The judgment follows the United States’ prior settlements with five other co-defendants named in the suit and serves as a stark reminder for telehealth companies, pharmacies, marketers, and healthcare providers of the government’s continued and increasingly aggressive focus on marketing tactics, patient outreach, and referral-related arrangements.
Inside the Alleged Scheme
According to the DOJ’s complaint, the case involved a compounding pharmacy and a network of marketers, telehealth providers, and prescribers working together to generate prescriptions reimbursed by TRICARE and Medicare in violation of the Federal Anti-Kickback Statute (AKS) and the False Claims Act (FCA). At a high level, the arrangement allegedly included the following:
- Commission-Based Marketing and Referral Network. The pharmacy operated as a “closed-door” compounding pharmacy that relied on independent contractor marketers to generate business, rather than traditional patient flow. These marketers: (i) identified potential patients; (ii) directed prescriptions to the pharmacy; and (iii) received a percentage of the pharmacy’s net profits from reimbursed claims.
- Direct-to-Consumer Marketing. Marketers were allegedly engaged to specifically target populations of retired military personnel, particularly in areas surrounding military bases, based on TRICARE’s historically high reimbursement rates for compounded drugs.
- Telehealth Prescribing Without Meaningful Clinical Interaction. The complaint alleges that patients were routed through telemedicine providers who: (i) lacked a preexisting relationship with the patient; (ii) often did not conduct meaningful clinical evaluations, as providers neither physically examined nor meaningfully communicated with the patient; and (iii) prescribed medications based on pre-filled prescription forms or marketer direction. In some instances, marketers allegedly paid for the patient’s telehealth visit.
- Product Selection Driven by Reimbursement, Not Medical Necessity. The government also alleged that the pharmacy ran “test claims” to determine which products would be covered by a patient’s insurance and yield the highest reimbursement and then instructed marketers on which prescriptions to pursue accordingly.
- Copay Waivers and Patient Inducements. The complaint also alleges that patient copayments were routinely waived to induce acceptance of the compounded drugs.
- Layered Financial Relationships to Obscure Kickbacks. The alleged scheme involved multiple layers of financial relationships, including commission payments to marketers, profit-sharing arrangements among various participants, and indirect compensation structures (including payments routed through third parties and family members).
Key Compliance Risks for Healthcare Companies and Providers
This case highlights several recurring risk areas across the healthcare industry:
- Marketing arrangements, if not properly structured, continue to present significant risk where compensation is tied, directly or indirectly, to prescriptions generated, patients referred, or revenue derived from government healthcare programs. Simply labeling an arrangement as “marketing” or “consulting” does not mitigate risk where compensation is linked to volume or value. In addition, many states maintain analogous prohibitions that may apply regardless of the payor source, which stakeholders must carefully consider.
- Telehealth models remain under heightened scrutiny, particularly where prescribing is influenced by marketers or third parties, lacks meaningful physician-patient interaction, is driven by pre-determined protocols tied to reimbursement, or involves financial relationships that influence clinical decision-making.
- Compensation structures and copay practices continue to be key areas of concern, as the government frequently cites both as evidence of improper inducement. Such arrangements are particularly scrutinized where compensation methodologies or the routine waiver of patient copayments may influence the utilization of federally reimbursable services.
Taken together, these themes reflect an expanding enforcement posture targeting business models that tie financial incentives, directly or indirectly, to federally reimbursable healthcare services.
How Frier Levitt Can Help
Frier Levitt’s Regulatory Compliance team works closely with pharmacies, telehealth companies, providers, and management services organizations to proactively identify and mitigate these risks. Our attorneys routinely assist clients in structuring compliant business models, evaluating marketing and telehealth arrangements, and addressing potential exposure before it becomes the subject of a government enforcement action. Contact Frier Levitt to speak with an attorney who can assess your current or proposed business models for compliance with federal and state law.
